Logo

NVCT

Nuvectis Pharma, Inc.

NVCT

Nuvectis Pharma, Inc. • NASDAQ
$6.24 ▲ 2.97% (+0.18)
Market Cap $159.80 M
52w High $11.52
52w Low $4.44
Dividend Yield 0%
P/E -4.55
Volume 77.47K
Outstanding Shares 25.61M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $7.794M ▲ $-7.462M ▼ 0% $-0.435 ▼ $-7.462M ▼
Q2-2025 $0 $6.595M ▲ $-6.334M ▼ 0% $-0.3 ▼ $-6.334M ▼
Q1-2025 $0 $5.568M ▼ $-5.332M ▲ 0% $-0.27 ▲ $-5.568M ▲
Q4-2024 $0 $6.449M ▲ $-6.248M ▼ 0% $-0.34 ▼ $-6.449M ▼
Q3-2024 $0 $4.359M $-4.153M 0% $-0.24 $-4.359M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $35.442M ▲ $35.587M ▲ $11.577M ▲ $24.01M ▲
Q2-2025 $26.793M ▼ $27.007M ▼ $10.135M ▲ $16.872M ▼
Q1-2025 $29.864M ▲ $30.148M ▲ $9.194M ▲ $20.954M ▲
Q4-2024 $18.533M ▲ $18.607M ▲ $8.894M ▲ $9.713M ▼
Q3-2024 $17.169M $17.307M $6.316M $10.991M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-9.891M ▼ $-4.494M ▼ $0 $13.143M ▲ $8.649M ▲ $-4.494M ▼
Q2-2025 $-6.334M ▼ $-3.367M ▲ $0 $296K ▼ $-3.071M ▼ $-3.367M ▲
Q1-2025 $-5.332M ▲ $-4.174M ▼ $0 $15.505M ▲ $11.331M ▲ $-4.174M ▼
Q4-2024 $-6.248M ▼ $-2.465M ▼ $0 $3.829M ▲ $1.364M ▲ $-2.465M ▼
Q3-2024 $-4.153M $-2.404M $0 $1.457M $-947K $-2.404M

Five-Year Company Overview

Income Statement

Income Statement Nuvectis is still a pure R&D story: it has no product revenue and has reported steady operating losses each year since inception. The loss per share has narrowed a bit recently, but the company is still firmly in investment mode, spending on research, trials, and overhead without any offsetting sales. This pattern is very typical for a small, clinical‑stage biotech that has not yet brought a drug to market.

Balance Sheet

Balance Sheet The balance sheet is simple and lean. Assets are modest and mostly made up of cash, with no financial debt, which reduces balance‑sheet risk. Shareholders’ equity is positive but thin, reflecting a small capital base that has only recently moved out of deficit. Overall, the company is lightly capitalized, with its financial strength closely tied to its available cash and future fundraising ability.

Cash Flow

Cash Flow Cash flows show a consistent, moderate cash burn from operations and essentially no spending on physical assets. All cash use is going into running the business and developing the pipeline rather than long‑term infrastructure. This means the company will likely remain dependent on new capital raises or partnerships over time, and its cash runway is a key variable to watch.

Competitive Edge

Competitive Edge Nuvectis operates in a highly competitive area of oncology, where many larger players also focus on targeted therapies. Its remaining lead asset, NXP900, has a differentiated mechanism that aims to shut down cancer signaling more completely and to tackle resistance to existing lung cancer drugs. That scientific angle offers some differentiation, but the termination of the NXP800 ovarian cancer program has reduced pipeline breadth and increased dependence on a single main program in a crowded field.

Innovation and R&D

Innovation and R&D The company’s strength lies in innovation and partnerships with top academic centers. NXP900 uses a novel “dual‑action” approach to inhibit key kinases involved in cancer growth and drug resistance, positioning it as a potential first‑ or best‑in‑class agent if clinical data are strong. However, the recent setback with NXP800 highlights the inherent uncertainty in drug development and leaves Nuvectis with a more concentrated R&D strategy centered on NXP900’s clinical progress and any future repositioning of NXP800.

Summary

Nuvectis is an early‑stage oncology biotech with no revenue, ongoing losses, and a balance sheet dominated by cash and no debt. Financially, it looks like a typical pre‑commercial biotech: dependent on external funding and clinical milestones. Strategically, the story now hinges on NXP900, a targeted cancer drug with a distinctive mechanism designed to overcome resistance to existing therapies. The discontinuation of NXP800 in ovarian cancer reduces diversification and raises execution risk, but the scientific rationale behind NXP900 and its academic backing remain key positives. Overall, this is a focused, high‑uncertainty development story where future clinical results and potential partnerships will largely shape the company’s outlook.

NEWS

November 25, 2025 · 8:00 AM UTC

Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC

Read more

November 4, 2025 · 8:15 AM UTC

CORRECTION: Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights

Read more

October 16, 2025 · 8:00 AM UTC

Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Read more

September 4, 2025 · 7:30 AM UTC

Nuvectis Pharma to Participate at the H.C. Wainwright 27th Annual Global Investment Conference

Read more